Publications by authors named "Winand Nm Dinjens"
Active surveillance instead of standard surgery after neoadjuvant chemoradiotherapy (nCRT) has been proposed for patients with oesophageal cancer. Circulating tumour DNA (ctDNA) may be used to facilitate selection of patients for surgery. We show that detection of ctDNA after nCRT seems highly suggestive of major residual disease.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the genetic changes involved in the development of cholangiocarcinoma (CCA) associated with primary sclerosing cholangitis (PSC), aiming to improve clinical management.
- It analyzed DNA from 44 PSC specimens to identify mutations and copy number variations (CNVs) at different stages of dysplasia and CCA, using advanced sequencing techniques.
- Results revealed distinct genetic alterations, with early-stage dysplasia showing specific CNVs, while later stages featured common mutations in genes such as TP53, ERBB2, and KRAS, highlighting potential new diagnostic strategies for PSC-CCA.
Article Synopsis
- There is a worry that a type of tumor in the salivary gland, called pleomorphic adenoma, can turn cancerous, which makes doctors want to treat it hard if it comes back.
- Scientists studied a specific case and found that changes in the DNA helped them see how the tumor changed from benign to cancerous.
- They identified particular DNA changes in the tumor that stayed the same even when it came back as cancer, showing that studying these changes can help doctors recognize when a tumor becomes malignant.
Objective: While oesophageal squamous cell carcinoma remains infrequent in Western populations, the incidence of oesophageal adenocarcinoma (EAC) has increased sixfold to eightfold over the past four decades. We aimed to characterise oesophageal cancer-specific and subtypes-specific gene regulation patterns and their upstream transcription factors (TFs). DESIGN: To identify regulatory elements, we profiled fresh-frozen oesophageal normal samples, tumours and cell lines with chromatin immunoprecipitation sequencing (ChIP-Seq).
View Article and Find Full Text PDFPurpose: To assess cost-effectiveness of routine screening for Lynch Syndrome (LS) in endometrial cancer (EC) patients ≤70years of age.
Methods: Consecutive EC patients ≤70years of age were screened for LS by analysis of microsatellite instability, immunohistochemistry and MLH1 hypermethylation. Costs and health benefit in life years gained (LYG) included surveillance for LS carriers among EC patients and relatives.
SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T).
Mod Pathol
June 2015
Article Synopsis
- The study aimed to assess the reliability of SDHB/SDHA immunohistochemistry for identifying patients at risk for familial pheochromocytoma/paraganglioma syndromes by investigating interobserver variability among expert pathologists using virtual microscopy on a large cohort (n=351).
- Results showed substantial agreement among pathologists, with 89.74% consensus on SDHB and 99.15% on SDHA immunohistochemistry, revealing patterns of protein expression related to different genetic mutations.
- The findings confirmed that SDHB/SDHA immunohistochemistry is a dependable method for identifying SDH-x mutations and could provide important insights for genetic variants of unclear significance, even when molecular genetic analysis is incomplete.
Background: This is a randomized, controlled trial of preoperative chemotherapy in patients undergoing surgery for oesophageal squamous cell carcinoma (OSCC). Patients were allocated to chemotherapy, consisting of 2-4 cycles of cisplatin and etoposide, followed by surgery (CS group) or surgery alone (S group). Initial results reported only in abstract form in 1997, demonstrated an advantage for overall survival in the CS group.
View Article and Find Full Text PDFMolecular biological challenges in he treatment of esophageal adenocarcinoma.
Expert Rev Gastroenterol Hepatol
December 2007
Despite improvements in detection and treatment, patients diagnosed with esophageal cancer continue to have a poor prognosis, with an increase in 5-year survival rates from 6 to 16% over the past 25 years. In the last decade there has been growing support for neoadjuvant therapy in patients with esophageal cancer. However, in approximately 30-60% of the patients no objective response is achieved after neoadjuvant chemotherapy and/or radiotherapy.
View Article and Find Full Text PDF